» Articles » PMID: 27233962

STAT2 Is Required for TLR-Induced Murine Dendritic Cell Activation and Cross-Presentation

Overview
Journal J Immunol
Date 2016 May 29
PMID 27233962
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

TLR-stimulated cross-presentation by conventional dendritic cells (cDCs) is important in host defense and antitumor immunity. We recently reported that cDCs lacking the type I IFN signaling molecule STAT2 are impaired in cross-presenting tumor Ags to CD8(+) T cells. To investigate how STAT2 affects cross-presentation, we determined its requirements for dendritic cell activation. In this study, we report that STAT2 is essential for the activation of murine female cDCs upon TLR3, -4, -7, and -9 stimulation. In response to various TLR ligands, Stat2(-/-) cDCs displayed reduced expression of costimulatory molecules and type I IFN-stimulated genes. The cDC responses to exogenous IFN-α that we evaluated required STAT2 activation, indicating that the canonical STAT1-STAT2 heterodimers are the primary signaling transducers of type I IFNs in cDCs. Interestingly, LPS-induced production of IL-12 was STAT2 and type I IFN receptor (IFNAR) dependent, whereas LPS-induced production of TNF-α and IL-6 was STAT2 and IFNAR independent, suggesting a specific role of the IFNAR-STAT2 axis in the stimulation of proinflammatory cytokines by LPS in cDCs. In contrast, R848- and CpG-induced cytokine production was less influenced by the IFNAR-STAT2 axis. Short kinetics and IFNAR blockade studies showed that STAT2 main function is to transduce signals triggered by autocrine type I IFNs. Importantly, Stat2(-/-) cDCs were deficient in cross-presenting to CD8(+) T cells in vitro upon IFN-α, CpG, and LPS stimulation, and also in cross-priming and licensing cytotoxic T cell killers in vivo. We conclude that STAT2 plays a critical role in TLR-induced dendritic cell activation and cross-presentation, and thus is vital in host defense.

Citing Articles

STAT signaling pathways in immune cells and their associated mechanisms in cancer pathogenesis.

Sohrabi S, Alipour S, Ghahramanipour Z, Masoumi J, Baradaran B Bioimpacts. 2025; 15:30030.

PMID: 39963570 PMC: 11830145. DOI: 10.34172/bi.30030.


Novel genetically engineered mouse models for clear cell renal cell carcinoma.

van der Mijn J, Laursen K, Fu L, Khani F, Dow L, Nowak D Sci Rep. 2023; 13(1):8246.

PMID: 37217526 PMC: 10203127. DOI: 10.1038/s41598-023-35106-7.


Epigenetic and transcriptomic reprogramming in monocytes of severe COVID-19 patients reflects alterations in myeloid differentiation and the influence of inflammatory cytokines.

Godoy-Tena G, Barmada A, Morante-Palacios O, de la Calle-Fabregat C, Martins-Ferreira R, Ferrete-Bonastre A Genome Med. 2022; 14(1):134.

PMID: 36443794 PMC: 9706884. DOI: 10.1186/s13073-022-01137-4.


The duality of STAT2 mediated type I interferon signaling in the tumor microenvironment and chemoresistance.

Canar J, Darling K, Dadey R, Gamero A Cytokine. 2022; 161:156081.

PMID: 36327541 PMC: 9720715. DOI: 10.1016/j.cyto.2022.156081.


Abnormalities of the type I interferon signaling pathway in lupus autoimmunity.

Gallucci S, Meka S, Gamero A Cytokine. 2021; 146:155633.

PMID: 34340046 PMC: 8475157. DOI: 10.1016/j.cyto.2021.155633.


References
1.
Starbeck-Miller G, Xue H, Harty J . IL-12 and type I interferon prolong the division of activated CD8 T cells by maintaining high-affinity IL-2 signaling in vivo. J Exp Med. 2013; 211(1):105-20. PMC: 3892973. DOI: 10.1084/jem.20130901. View

2.
Bevan M . Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J Exp Med. 1976; 143(5):1283-8. PMC: 2190184. DOI: 10.1084/jem.143.5.1283. View

3.
Ivashkiv L, Donlin L . Regulation of type I interferon responses. Nat Rev Immunol. 2013; 14(1):36-49. PMC: 4084561. DOI: 10.1038/nri3581. View

4.
Durbin R, Kotenko S, Durbin J . Interferon induction and function at the mucosal surface. Immunol Rev. 2013; 255(1):25-39. PMC: 5972370. DOI: 10.1111/imr.12101. View

5.
Wonderlich J, Shearer G, Livingstone A, Brooks A . Induction and measurement of cytotoxic T lymphocyte activity. Curr Protoc Immunol. 2008; Chapter 3:3.11.1-3.11.23. DOI: 10.1002/0471142735.im0311s72. View